Zynex, Inc , through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
infoZynex is a small cap stock with a total market cap of 288.12M.
infoThey trade on the NASDAQ and had their IPO 19 years and 5 months ago.
infoZynex currently employs 900 people.
infoAs of Wednesday, Aug 23 2023, Zynex’s share price is $8.02.
News Relating to Zynex
Seeking Alpha
Zynex, Inc. (ZYXI) Q2 2023 Earnings Call Transcript
Thursday Jul 27 2023 at 20:14
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2023 Earnings Conference Call July 27, 2023 4:15 PM ET Company Participants Quinn Callanan – Investor Relations Thomas Sandgaard – Chairman, President and Chief Executive Officer Anna Lucsok – Chief Operating Officer Donald Gregg – Vice President, Zynex Monitoring Solutions Daniel Moorhead – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Operator Good day ladies and gentlemen, and welcome to the Zynex Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Zacks Investment Research
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
Thursday Jul 27 2023 at 18:28
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.08 per share a year ago.
PRNewsWire
Zynex, Inc. Sets Second Quarter 2023 Earnings Call
Thursday Jul 20 2023 at 09:15
ENGLEWOOD, Colo. , July 20, 2023 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.
Seeking Alpha
Zynex: Strong Growth And Profitability Amid Financial Concerns
Sunday Jul 16 2023 at 03:33
Zynex, a medical device manufacturer, has reported a 36% year-over-year increase in revenue in Q1 2023, reaching $42.2 million, with a 14% increase in net income. Despite short-term underperformance, the company shows strong profitability and growth potential, with a gross profit margin of nearly 80% and a substantial return on equity of 24.58%. Zynex’s robust growth strategy and commitment to operational efficiency suggest a promising outlook, despite concerns related to its financial stability and stock performance.
The Motley Fool
Why Shares of Zynex Are Up Wednesday
Wednesday Jun 14 2023 at 12:33
Zynek makes electrotherapy devices to control pain. The company grew revenue and net income in the first quarter.
InvestorPlace
7 Stocks With 1,000% Upside Potential
Tuesday May 30 2023 at 18:34
While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.
Seeking Alpha
Zynex, Inc. (ZYXI) Q1 2023 Earnings Call Transcript
Saturday Apr 29 2023 at 14:49
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2023 Earnings Conference Call April 27, 2023 4:15 PM ET Company Participants Louisa Smith – Investor Relations Thomas Sandgaard – Chairman, President and Chief Executive Officer Anna Lucsok – Chief Operating Officer Donald Gregg – Vice President, Zynex Monitoring Solutions Daniel Moorhead – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Adam Maeder – Piper Sandler Yi Chen – H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2023 Earnings Conference Call.
Zacks Investment Research
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
Thursday Apr 27 2023 at 19:00
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.03 per share a year ago.
PRNewsWire
Zynex, Inc. to Announce First Quarter 2023 Financial Results
Wednesday Apr 19 2023 at 09:15
ENGLEWOOD, Colo. , April 19, 2023 /PRNewswire/ — Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2023 financial results on Thursday, April 27, 2023.
Seeking Alpha
Zynex: Seems An Odd Short Target
Tuesday Apr 18 2023 at 12:23
Zynex: Seems An Odd Short Target
Proactive Investors
Zynex soars after 4Q earnings and revenue beat Street estimates
Monday Mar 13 2023 at 15:24
Zynex Inc shares soared after the company posted fourth quarter earnings and revenue that beat Wall Street analyst estimates. For the period ended December 31, 2022, the Englewood, Colorado-based medical device manufacturer reported earnings of $0.20 per share on revenue of $48.8 million.
Zacks Investment Research
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
Monday Mar 13 2023 at 10:44
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PRNewsWire
Zynex, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results
Thursday Feb 23 2023 at 09:15
ENGLEWOOD, Colo. , Feb. 23, 2023 /PRNewswire/ — Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter and full-year 2022 financial results on Monday, March 6, 2023.
Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month – Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)
Monday Feb 13 2023 at 08:28
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Seeking Alpha
Zynex Is A Quality Company, But You Must Pay For Quality
Tuesday Jan 31 2023 at 22:30
Products sold in the past by Zynex for pain management have failed to penetrate the market. Zynex’s new products are radically different from their predecessors: more specific and innovative.
GuruFocus
3 Small-Cap Bargains Gurus Are Buying
Monday Dec 05 2022 at 18:10
According to recent data from Bank of America’s ( BAC , Financial) BofA Securities, the small-cap stocks on the Russell 2000 index are now trading at their lowest average forward price-earnings ratio since 2009. The Russell 2000 is also down 19% year to date versus the S&P 500’s 16% loss.
Seeking Alpha
Zynex: A Growing Stock In A Bearish Market
Wednesday Nov 23 2022 at 14:15
Zynex, Inc.’s business is inflation-resistant, and the monitor division could be a game changer. Quarterly results were positive, and Zynex continues to operate at its best.
Seeking Alpha
Zynex, Inc. (ZYXI) Q3 2022 Earnings Call Transcript
Thursday Oct 27 2022 at 20:47
Zynex, Inc. (NASDAQ:ZYXI ) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Financial Officer Anna Lucsok – Chief Operating Officer Donald Gregg – Vice President-Zynex Monitoring Solutions Conference Call Participants Simran Kaur – Piper Sandler Jeffrey Cohen – Ladenburg Thalmann Yi Chen – H.C. Wainwright Marc Wiesenberger – B.
Zacks Investment Research
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
Thursday Oct 27 2022 at 19:33
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
InvestorPlace
7 Under-the-Radar Growth Stocks With 200% Growth Potential
Monday Oct 17 2022 at 12:04
Rising interest rates and growing fears of a recession have sent growth stocks plunging in the past year. Yet while some growth names have deservingly moved to lower prices and could keep tumbling, there are many under-the-radar growth stocks that have either become oversold or have seen their performance blunted by investors’ poor sentiment.
Seeking Alpha
Short Squeeze Candidate With Low PEG Ratio: Zynex
Wednesday Oct 05 2022 at 15:48
Zynex has succumbed to extensive short selling in 2021-22 that may be in the process of reconsidering bearish bets. Projected growth rates for the company are exceptionally positive, on new product releases.
InvestorPlace
7 Hot Small-Cap Stocks to Buy in September
Friday Sep 02 2022 at 06:45
In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.
PRNewsWire
Zynex Medical to Participate in H.C. Wainwright Annual Global Investment Conference
Thursday Sep 01 2022 at 09:15
ENGLEWOOD, Colo. , Sept. 1, 2022 /PRNewswire/ — Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company’s management will participate virtually in the H.C.
Seeking Alpha
Zynex Cures The Pain Of Its Shareholders: Q2 Results
Monday Aug 01 2022 at 11:44
Zynex beat analysts’ estimates despite the recession. Zynex is committed to bringing value to its shareholders with a new share buyback round.
Seeking Alpha
Zynex, Inc. (ZYXI) CEO Thomas Sandgard on Q2 2022 Results – Earnings Call Transcript
Thursday Jul 28 2022 at 21:16
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2022 Results Conference Call July 28, 2022 4:15 PM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Financial Officer Anna Lucsok – Chief Operating Officer Don Gregg – Vice President of Zynex Monitoring Solutions Conference Call Participants Simran Kaur – Piper Sandler Jeffrey Cohen – Ladenburg Thalmann Marc Wiesenberger – B. Riley Securities Yi Chen – H.C.
PRNewsWire
Zynex, Inc. to Announce Second Quarter 2022 Financial Results
Wednesday Jul 20 2022 at 09:15
ENGLEWOOD, Colo. , July 20, 2022 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report second quarter 2022 financial results on Thursday, July 28, 2022.
Seeking Alpha
Zynex’s (ZYXI) CEO Thomas Sandgaard on Q1 2022 Results – Earnings Call Transcript
Thursday Apr 28 2022 at 21:10
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2022 Earnings Conference Call April 28, 2022 4:15 PM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Anna Lucsok – Chief Operating Officer Don Gregg – Vice President of Zynex Monitoring Solutions Dan Moorhead – Chief Financial Officer Conference Call Participants Marc Wiesenberger – BRiley Jeffrey Cohen – Ladenburg Thalmann Yi Chen – H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
Zacks Investment Research
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
Thursday Apr 28 2022 at 18:48
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PRNewsWire
Zynex, Inc. to Announce First Quarter 2022 Financial Results
Monday Apr 18 2022 at 07:00
ENGLEWOOD, Colo. , April 18, 2022 /PRNewswire/ — April 18, 2022 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2022 financial results on Thursday, April 28, 2022.
Seeking Alpha
Zynex, Inc’s. (ZYXI) CEO Thomas Sandgaard on Q4 2021 Results – Earnings Call Transcript
Thursday Feb 24 2022 at 22:37
Zynex, Inc’s. (ZYXI) CEO Thomas Sandgaard on Q4 2021 Results – Earnings Call Transcript
Zynex Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Zynex’s Altman Z-score is 4.44 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Zynex Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 2 insiders have sold $270.72K of common stock in Zynex on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Zynex’s Income Quality of 1.07 is greater than its Industry Group of 0.68 (57.4% greater)
Zynex’s Income Quality of 1.07 is greater than its Major Industry Group of 0.71 (50.7% greater)
Zynex’s Income Quality of 1.07 is greater than its Sector of 0.75 (42.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Zynex’s Current Ratio of 7.63 is greater than its Industry Group of 3.36 (127.1% greater)
Zynex’s Current Ratio of 7.63 is greater than its Major Industry Group of 3.13 (143.8% greater)
Zynex’s Current Ratio of 7.63 is greater than its Sector of 2.6 (193.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (16.7 & -1.02)
Cannot compare a negative PE Ratio (16.7 & -0.58)
Cannot compare a negative PE Ratio (16.7 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Zynex’s PB Ratio of 4.63 is greater than its Industry Group of 1.9 (143.7% greater)
Zynex’s PB Ratio of 4.63 is greater than its Major Industry Group of 1.93 (139.9% greater)
Zynex’s PB Ratio of 4.63 is greater than its Sector of 1.62 (185.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Zynex’s ROE of 0.28 is greater than its Industry Group of -0.26 (207.7% greater)
Zynex’s ROE of 0.28 is greater than its Major Industry Group of -0.09 (411.1% greater)
Zynex’s ROE of 0.28 is greater than its Sector of -0.03 (1033.3% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Zynex’s ROCE of 0.15 is greater than its Industry Group of -0.27 (155.6% greater)
Zynex’s ROCE of 0.15 is greater than its Major Industry Group of -0.14 (207.1% greater)
Zynex’s ROCE of 0.15 is greater than its Sector of -0.04 (475.0% greater)
Derived from SEC.GOV filing dataopen_in_new